Since 2003, Philadelphia, PA.-based BioAdvance has committed more than $16m to 26 life sciences companies and 17 pre-seed projects. Its portfolio companies develop products to treat health problems such as Alzheimer’s disease, cancer, diabetes, head trauma and infectious diseases.
BioAdvance, a leading seed- and pre-seed investor in life sciences companies, announced the expansion of its new investment team.
Shahram Hejazi, PhD, a chief executive business leader in medical and life science technology with experience in growing early stage ventures and expanding large global business units within Fortune 500 companies will join Marie Lindner, M.D., a medical doctor, a global pharmaceutical/biotechnology executive and C-level executive experience in the biotech and entrepreneurial life sciences space.
Barbara S. Schilberg, managing director and CEO of BioAdvance, said: “Marie and Shahram bring significant diversity and depth of expertise to BioAdvance.
“Together they bring scientific, global pharmaceutical and medical technology expertise – from both a business and operations perspective – which allows them to provide critical advice and leadership to support applicant companies and the needs of the BioAdvance portfolio”.